

**Platelet Dysfunction in Chediak-Higashi Syndrome-Affected Cattle**Mitsuya SHIRAISHI<sup>1)</sup>, Hiroyuki OGAWA<sup>2)</sup>, Masahiro IKEDA<sup>1)</sup>, Sachiko KAWASHIMA<sup>1)</sup> and Katsuaki ITO<sup>1)\*</sup><sup>1)</sup>Department of Veterinary Pharmacology, Faculty of Agriculture, Miyazaki University, Miyazaki 889-2192 and <sup>2)</sup>Graduate School of Agriculture and Life Science, The University of Tokyo, Tokyo 113-8657, Japan

(Received 28 January 2002/Accepted 23 April 2002)

**ABSTRACT.** A serious symptom of cattle affected with Chediak-Higashi syndrome (CHS) is a bleeding tendency. This diathesis is characterized by insufficient platelet aggregation as a result of depressed response to collagen. One possible cause for the depression is a decrease in contribution of endogenous agonists such as ADP or thromboxane A<sub>2</sub>, which are released following collagen stimulation. However, these endogenous agonists play only a minor role in collagen-induced aggregation of bovine platelets. More importantly, activation of phospholipase C as a result of a direct action of collagen is depressed, leading to a depression of Ca<sup>2+</sup> mobilization, in platelets from CHS-affected cattle. Several types of collagen receptor are proposed to work in concert to induce aggregation. Among them, glycoprotein VI (GPVI) and GPIa/IIa (integrin  $\alpha 2\beta 1$ ) have been supposed to play dominant roles in collagen-induced aggregation. However, there are arguments about the role of each receptor, especially the role of GPIa/IIa, and the crosstalk between receptors. Recently, we reported that the Ca<sup>2+</sup> signaling produced by rhodocytin, which had been first reported to be an agonist for the collagen receptor GPIa/IIa, produced much less Ca<sup>2+</sup> signaling in CHS platelets than in normal ones, whereas that produced by GPVI activators was normal. These suggest that GPIa/IIa or the rhodocytin-associated pathway is impaired in CHS platelets. CHS platelets are valuable to reassess the mechanism of collagen-dependent signal transduction system and to delineate the inter-relationship among collagen receptors.

**KEY WORDS:** Ca<sup>2+</sup> signaling, cattle, Chediak-Higashi syndrome, collagen receptor, platelet.

*J. Vet. Med. Sci.* 64(9): 751-760, 2002

Chediak-Higashi syndrome (CHS) is an autosomal recessive genetic disease, which is manifested of partial oculocutaneous albinism, increased susceptibility to infections, and a bleeding tendency, and is found in humans, cattle, minks, cats, mice, rats and fox [27, 29, 31, 44, 48, 49, 63]. Most human and animal patients affected with CHS show bleeding diathesis. The bleeding diathesis of CHS results from impairment of platelet functions. In fact, *in vitro* aggregation studies using platelets from CHS patients revealed that aggregation induced by collagen, which is an important platelet activator to form a thrombus when a vessel wall is injured, was remarkably impaired in platelets from almost all patients. In this review, we first describe abnormality in CHS platelets and possible causes for insufficient aggregation to collagen in CHS platelets.

We have recently demonstrated that handling of cytosolic Ca<sup>2+</sup> due to a direct action of collagen was abnormal in platelets from Japanese Black cattle affected with CHS [59, 61]. This observation suggests that a collagen receptor-Ca<sup>2+</sup> signaling system is impaired in CHS-affected platelets. There are several subtypes of collagen receptor on platelets and their interrelationship seems to be very complicated, so that the mechanism of collagen-induced aggregation has only partially been elucidated. On this standpoint, the study to explore a cause for insufficient aggregation of CHS platelets will give a new insight into a collagen receptor-associated signaling pathway. Mainly based on our data, therefore, we next introduce a current idea about a receptor responsible for the impaired response to collagen in platelets

from CHS-affected cattle and inter-relationship among collagen receptors.

**CHARACTERISTICS OF CHEDIAK-HIGASHI SYNDROME**

CHS was initially found as the case in humans [4] and named as CHS after the works by Chediak, who described hematological characteristics of the disorder [14], and Higashi, who found giant peroxidase-containing granules within cells from the disease-affected patients [19]. In most human patients affected with CHS, death often occurs in the first decade of life due to infection, bleeding, or development of the 'accelerated phase', which is characterized by a lymphoproliferative syndrome with lymphohistiocytic infiltration. CHS in cattle is found in Hereford [49], Japanese Black [69] and Brangus breeds [2]. In Japan, Japanese Black cattle affected with CHS are frequently seen in South Kyusyu area (Miyazaki and Kagoshima Prefectures) [46] and infrequently in other places. A simple autosomal recessive condition was documented in Hereford and Japanese Black cattle [48, 68].

Symptoms of CHS seen in humans and cattle are listed in Table 1. Patients affected with CHS show a variable degree of partial oculocutaneous albinism, increased susceptibility to infections, and a bleeding tendency. In cattle affected with CHS, the most important clinical manifestations are bleeding diathesis. In 1976, Bell *et al.* reported that, during past 7 years, 20 of 56 deaths among the Hereford cattle maintained at Washington State University could be directly associated with hemorrhage [5]. Ogawa *et al.* reported that 56 animals of more than 200 bleeding Japanese Black cattle

\* CORRESPONDENCE TO: ITO, K., Department of Veterinary Pharmacology, Faculty of Agriculture, Miyazaki University, Miyazaki 889-2192, Japan.

Table 1. Clinical signs of Chediak-Higashi syndrome in humans and cattle

	Human	Hereford	Japanese Black
Infection	Dermatitis	Abscess ‡	Abscess ‡
	Rhinopharyngitis	Pneumonia	Pneumonia
	Otitis	Endocarditis	Endocarditis
	Oral ulcer	Nephritis	Nephritis
	Abscess ‡	Dermatitis	Dermatitis
	Pneumonia	Diarrhea	
	Nephritis	Upper respiratory infection	
	Hepatitis	Peritonitis	
	Peritonitis		
Bleeding	Easy bruisability	Bleeding following surgical procedures	Bleeding following surgical procedures
	Mucosal bleeding	Hematoma	Hematoma
	Epitaxis	Mucosal bleeding	Epitaxis
			Melena Umbilical bleeding
Ocular findings	Pale iris	Pale iris	Pale iris
	Photophobia	Photophobia	Abnormal fundic reflection
	Nystagmus	Abnormal fundic reflection	
	Abnormal fundic reflection		
Hypopigmentation of skin, and hair	Present	Present	Present
Neurologic findings*	Present	Absent	Absent
Accelerated phase†	Present	Absent	Absent

\* Peripheral and cranial neuropathy, autonomic dysfunction, weakness, sensory deficits, hyporeflexia, clumsiness, and seizures. † Fever, anemia, neutropenia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy and jaundice. ‡ Found in muscle, lung, skin and liver.

examined were diagnosed as CHS, and a typical sign of the disease among the affected cattle was bleeding disorder [46].

Human CHS patients most commonly exhibit easy bruisability, mucosal bleeding and epistaxis. The bleeding manifestations are mild to moderate [12, 13]. Severe gastrointestinal hemorrhage was observed in the late stage of the disease in child CHS patients, which may be caused by thrombocytopenia in the accelerated phase. The bleeding tendency in Hereford cattle with CHS is often observed as fibrosis in resolution of large subcutaneous accumulations of blood and as production of numerous, firm subcutaneous nodules at sites of previous trauma [5]. Bleeding manifestations of Japanese Black cattle affected with CHS are observed as excess bleeding during or after castration, development of superficial or intrapubic (or abdominal) hematoma [46].

Prolonged bleeding time has been reported in most of affected animal species [2, 5, 6, 12, 16, 35, 46, 63]. On the other hand, coagulation system is normal in humans, Japanese Black cattle and cats affected with CHS [12, 35, 46]. Platelet count is normal in most cases of humans, Japanese Black, Hereford cattle and minks [5, 6, 46]. These findings imply that the bleeding diathesis of CHS may result from

impairment of platelet functions but not from thrombocytopenia or coagulopathy.

#### STRUCTURAL OR FUNCTIONAL ABNORMALITIES IN CHS PLATELETS

Platelets are small discoid cell fragments (approximately  $0.5 \times 3.0 \mu\text{m}$  long) produced from megakaryocytes in bone marrow. Under a normal condition, platelets are not adhesive to a vessel wall and do not adhere each other. When a blood vessel is damaged at the luminal side, however, platelets adhere to subendothelial extracellular matrix (ECM) and become activated (Fig. 1). Collagen is rich in the ECM within vessel wall, and provides an important site when platelets adhere to the exposed ECM. The adhesion is mediated through indirect and direct interaction. Under high shear stress, glycoprotein Ib (GPIb) interacts indirectly with collagen via von Willebrand factor (vWf) [56]. Several surface glycoproteins on platelet have been identified as collagen receptors including most importantly glycoprotein VI (GPVI) and GPIa/IIa (also termed  $\alpha 2\beta 1$ ) [43, 65]. Activated platelets change the shape from a discoid to a spheroid form, accompanied by formation of filopodia-like structures. This is followed by secretion of granule contents, pro-




Fig. 1. Sequential events from injury to a vessel wall to platelet aggregation. When a blood vessel is damaged, the subendothelial layer is exposed to platelets. Platelets are tethered to the layer through interaction of von Willebrand factor (vWf) and glycoprotein Ib/IX (GPIb/IX) (A). Then, platelets firmly adhere to collagen, mediated by GPIa/IIa and GPVI. Activated platelets change the shape from a discoid to a spheroid form, accompanied by formation of filopodia-like structure and spread out on ECM. GPIIb/IIIa and vWF are involved in the spreading. This is followed by secretion of granule contents (ADP) and production of thromboxane A<sub>2</sub> (TXA<sub>2</sub>), which augment aggregation (B). Then, platelets aggregate to form a thrombus. The binding of fibrinogen and vWF to GPIIb/IIIa ( $\alpha$ Ib $\beta$ 3) is involved in this stage. This scheme is based on the conventional idea that GPIa/IIa and GPVI play major roles. The significance of GPIa/IIa is now challenged (see text and Fig. 3). EC; endothelial cell, SMC; smooth muscle cell.

duction of thromboxane A<sub>2</sub> (TXA<sub>2</sub>) and finally platelet aggregation, in the stage of which GPIIb/IIIa activated on platelet surface binds to fibrinogen with high affinity. Platelet activation includes these whole processes and it is vital to the formation of a haemostatic plug under physiological or pathophysiological conditions.

**Abnormal platelet aggregation to collagen:** Table 2 lists data from *in vitro* aggregation experiments using platelets from CHS patients. Decreased aggregative response to collagen is a common feature in almost all patients affected

with CHS (Fig. 2A). Besides, in human patients with CHS, impairment of epinephrine-induced aggregation was also observed [1, 5, 12]. Platelet aggregation by ADP is normal or sometimes slightly decreased with a tendency to disaggregate in CHS platelets. Phorbol-12-myristate 13-acetate (PMA)-induced aggregation was normal in Japanese Black cattle with CHS [66], while it was depressed in mice with CHS [53]. It is agreed that the bleeding tendency in CHS is attributable to abnormal platelet activation in response to collagen. In the following sections, we describe possible

Table 2. Platelet aggregation induced by various agonists in animals affected with Chediak-Higashi syndrome

Animal	Coll	ADP	Thr	Epi	A23187	PMA	5-HT	AA	Author
Human	A	N	-	A	-	-	-	-	Buchanan and Handin [12]
	A	A	-	A	-	-	-	-	Bell <i>et al.</i> [5]
	V	V	-	V	-	-	-	-	Boxer <i>et al.</i> [13]
	N	N	-	-	-	-	A	-	Parmley <i>et al.</i> [50]
	A	A*	-	-	-	-	-	A	Weening <i>et al.</i> [73]
	-	N	A	-	-	-	-	N	Rendu <i>et al.</i> [55]
	A	N	-	-	-	-	-	-	Legrand & Nurden [30]
	A*	A*	-	A	V	-	-	A	Apitz-Castro <i>et al.</i> [1]
Cattle/Her	A	A	-	0	-	-	-	-	Bell <i>et al.</i> [5]
	A	A*	N	-	-	N	-	-	Suzuki <i>et al.</i> [66]
Cattle/JB	A	A*	-	-	-	-	-	-	Ogawa <i>et al.</i> [46]
	A	A*	-	-	-	-	-	-	Shiraishi <i>et al.</i> [59]
	A	N	-	-	-	-	-	-	Bell <i>et al.</i> [6]
Mink	A	A	-	0	-	-	A	-	Meyers <i>et al.</i> [35]
Cat	A	A*	-	0	-	-	V	A	Sjaastad, <i>et al.</i> [62]
Fox	A	A*	-	0	-	-	-	-	Pratt <i>et al.</i> [53]
Mice	A†	-	A†	-	A†	A	-	-	Ozaki <i>et al.</i> [47]
Rat	A	A*	-	-	-	-	-	-	

Her, Hereford; JB, Japanese Black. Coll, collagen; Thr, thrombin; Epi, epinephrine; 5-HT, serotonin; AA, arachidonic acid. A, abnormal; N, normal; 0, no aggregation; V, variable. \*, tend to disaggregate; †, only at low concentration.

causes underlying the depressed responsiveness to collagen in CHS platelets.

**Storage pool deficiency:** Ultrastructural examination of platelets revealed that a shape and size of platelets from CHS-affected Hereford [54], Japanese Black cattle [46] and humans [55] was normal. At least three types of secretory granule exist in platelets; lysosomes,  $\alpha$ -granules, and dense granules (otherwise called  $\delta$ -granules). Interestingly, an abnormality in lysosomes, which is typical for CHS leukocytes, was not observed in platelets from cattle [34, 37, 54], cats [34], minks [34] and most humans affected with CHS [13, 55].  $\alpha$ -Granules in CHS platelets, which contain vWf, platelet factor 4, and thrombospondin, were similar in structure and quantity to those in normal platelets [33, 34, 55]. Dense granules contain ADP, ATP, serotonin and  $\text{Ca}^{2+}$ . ADP is released from dense granules to extracellular space when platelets are activated by various kinds of stimulation, and acts as a secondary agonist, thus playing an important role in aggregation of human platelets. A dense body in human CHS platelets is irregular [32] and a number of dense granules in platelets from Hereford and Japanese Black cattle [33, 34, 36, 46, 54], humans [32, 55], and rats [47] was less in patients with CHS than in normal controls. Dense granule precursors in megakaryocytes were absent in CHS-affected Hereford cattle [37]. In accord with these observations, contents in dense granules (ADP, ATP, serotonin and  $\text{Ca}^{2+}$ ) were greatly decreased in humans and animals affected with CHS [6, 13, 33, 35, 46, 47, 53, 63]. These observations lead to the hypothesis that a decrease in release of ADP from a dense body ( $\delta$ -storage pool deficiency,  $\delta$ -SPD) is a major cause for defective aggregation in CHS platelets [5, 13, 33, 55].

Since ADP plays an important role in the collagen-induced aggregation in human platelets [24, 59],  $\delta$ -SPD could probably be responsible for decreased responsiveness

to collagen in human CHS platelets. However, Nieuwenhuis *et al.* reported that 23% of patients having  $\delta$ -SPD showed normal aggregation responses to collagen [44]. Furthermore, it has been reported that ADP content in bovine platelets (normal Hereford cattle) is only about 30% of human platelets [5, 34]. Therefore, it is not clear whether a decreased release of endogenous ADP is involved in the blunted collagen-induced aggregation of CHS platelets. In platelets from normal Japanese Black cattle, aggregation induced by collagen was only partially inhibited by AR-C66096, an antagonist to ADP P2Y<sub>12</sub> purinoceptor, which mediates the ADP-induced aggregation in human and bovine platelets [18, 59]. The extent of ADP-dependent aggregation seems to be 20 to 30% of the total aggregation response to collagen in platelets from normal cattle, whereas it was negligible in the response of platelets from CHS-affected cattle [24, 59]. This suggests that endogenous ADP is only partially involved in the collagen-induced aggregation of bovine platelets and that a decrease in release of ADP is partially responsible for the blunted response to collagen in CHS platelets. However, a decreased release of endogenous ADP is not the sole mechanism for impaired aggregation to collagen in platelets from CHS-affected cattle, because the aggregation response to collagen in normal platelets after blockade of P2Y<sub>12</sub> purinoceptors was still much greater than that in CHS platelets [59].

**Impairment of thromboxane A<sub>2</sub> production:** TXA<sub>2</sub> is released from activated platelets as a result of sequential activation of phospholipase A<sub>2</sub>, cyclooxygenase-1 and thromboxane synthase and acts as a secondary agonist as well as ADP on platelets [41, 52, 62]. A decrease in TXA<sub>2</sub> production could be a case in human CHS platelets because aggregation to exogenous arachidonic acid, which is converted to TXA<sub>2</sub>, was reported to decline in two human CHS cases [1, 73]. Suzuki *et al.* suggested that impairment of




Fig. 2. Characteristics of aggregation and  $[Ca^{2+}]_i$  responses in bovine CHS platelets. A, aggregation and  $[Ca^{2+}]_i$  responses to collagen. When influences of endogenous agonists (TXA<sub>2</sub> and ADP) were excluded, platelets were pretreated with 1 mM aspirin (a cyclooxygenase inhibitor), 100 nM AR-C66096 (a P2Y<sub>12</sub> receptor antagonist) and 100  $\mu$ M adenosine 3'-phosphate 5'-phosphosulfate (A3P5PS, a P2Y<sub>1</sub> receptor antagonist). B,  $[Ca^{2+}]_i$  response to 3 ng/ml convulxin, a GPVI activator. C,  $[Ca^{2+}]_i$  response to 10 nM rhodocytin, a putative GPIIb/IIIa activator. Reproduced from [58–60].

production of TXA<sub>2</sub> is a main cause for a depression of aggregation to collagen in CHS platelets since indomethacin, a cyclooxygenase inhibitor, inhibited the collagen-induced aggregation in normal platelets, while it exerted a smaller effect on the aggregation in CHS platelets from Japanese Black cattle [66]. Unlike human platelets, however, arachidonic acid metabolites seem to play a negligible role in bovine platelets, because cyclooxygenase inhibitors showed no effect on aggregation response to collagen, ADP or platelet-activating factor in platelets from healthy cattle [11, 17, 24]. Consistent with these reports, our study

revealed that aggregation or an increase in cytosolic Ca<sup>2+</sup> concentration ( $[Ca^{2+}]_i$ ) in response to collagen was scarcely affected by cyclooxygenase inhibitors and U446619, a TXA<sub>2</sub> mimetic, caused no aggregation response and only a slight increase in  $[Ca^{2+}]_i$  in bovine platelets [59]. In contrast to Suzuki *et al.*'s paper [66], the  $[Ca^{2+}]_i$  response to collagen in bovine CHS platelets was slightly decreased by pretreatment with cyclooxygenase inhibitors, whereas it was not affected in normal platelets [59–61]. Probably, contribution of TXA<sub>2</sub> increased in the collagen-induced response of CHS platelets as a compensation for a decrease in release of ADP,




Fig. 3. Speculative model for platelet collagen receptors. Until recently, GPVI and GPIa/IIa are supposed to be predominant receptors for collagen in platelets. However, recent works from Germany and Switzerland [7, 42] proposed that GPIa/IIa is not essential for collagen-induced activation, at least in mouse platelets. It has not been determined whether rhodocytin binds to GPIa/IIa in bovine platelets. If rhodocytin does not bind to GPIa/IIa, our study [61] suggests that another receptor, which is sensitive to rhodocytin, participates in the collagen-induced activation. This receptor probably delivers a signal for full activation of GPVI when collagen acts on platelets. It is likely that CHS platelets lack a receptor that binds rhodocytin or a signal existing downstream of the receptor. This pathway is sensitive to cytochalasin D [61]. GPVI is coupled to Fc receptor  $\gamma$ -chain (FcR $\gamma$ ) and a signal from GPVI is probably transmitted to several tyrosine kinases and adaptor proteins (not shown in the figure), then activates the tyrosine kinase Syk to phosphorylate PLC $\gamma$ . It is possible that GPIa/IIa or the rhodocytin-sensitive receptor also activates PLC $\gamma$ , since it has been shown that rhodocytin induces tyrosine phosphorylation of Syk and PLC $\gamma$  in human platelets [67]. Signaling system downstream of GPVI, which leads to Ca<sup>2+</sup> mobilization, is nearly intact in CHS platelets, when GPVI is activated by convulxin.

although we do not know the mechanism for the compensation. Taken together, we think that the primary cause for the impaired response to collagen in platelets from cattle affected with CHS is not a decreased release of endogenous agonists.

**Ca<sup>2+</sup> mobilization and phospholipase C activation:** Ca<sup>2+</sup> is an important intracellular messenger within many cells [8]. In platelets, it is agreed that an increase in [Ca<sup>2+</sup>]<sub>i</sub> is an initial event required for activation by almost all agonists [57, 64]. Collagen gradually increased [Ca<sup>2+</sup>]<sub>i</sub> in bovine CHS platelets, while it more rapidly increased [Ca<sup>2+</sup>]<sub>i</sub> in normal platelets. In CHS platelets, the maximum increase in [Ca<sup>2+</sup>]<sub>i</sub> induced by collagen at each concentration was significantly lower than in normal platelets [59]. The fraction

of collagen-induced Ca<sup>2+</sup> mobilization that was independent of endogenous agonists in CHS platelets was only about 15% of that in normal platelets [61] (Fig. 2A). This result suggests that a Ca<sup>2+</sup> signaling mechanism as a consequence of the direct action of collagen is defective in bovine CHS platelets and that this defect is important in the etiology of insufficient aggregation.

A rise in [Ca<sup>2+</sup>]<sub>i</sub> caused by receptor agonists usually consists of two components: Ca<sup>2+</sup> release from intracellular Ca<sup>2+</sup> stores and Ca<sup>2+</sup> entry across the plasma membrane [57]. Ca<sup>2+</sup> release from intracellular Ca<sup>2+</sup> stores is mediated by inositol 1,4,5-trisphosphate (Ins(1,4,5)P<sub>3</sub>) produced following activation of phospholipase C (PLC) [9]. In our study with bovine platelets [60], collagen increased cyto-

lic  $\text{Ins}(1,4,5)\text{P}_3$ , and the collagen-induced  $\text{Ca}^{2+}$  mobilization was inhibited by treatment with U73122, a PLC inhibitor [10, 70]. Thus, the collagen-induced  $\text{Ca}^{2+}$  mobilization depends on the PLC activity. The type of PLC involved in the collagen-induced  $\text{Ca}^{2+}$  mobilization is  $\text{PLC}\gamma$ , which is different from the type ( $\text{PLC}\beta$ ) associated with a receptor coupled to heterotrimeric GTP-binding protein (e.g. ADP or thrombin) [72]. In contrast to  $\text{PLC}\beta$ ,  $\text{PLC}\gamma$  is activated through tyrosine phosphorylation [26]. In platelets from cattle with CHS, the collagen-induced increase in  $\text{Ins}(1,4,5)\text{P}_3$  was greatly depressed compared with that in normal platelets [61]. Therefore, a cause for the insufficient  $\text{Ca}^{2+}$  mobilization in CHS platelets is present in the pathway between the binding of collagen to receptors and the activation of  $\text{PLC}\gamma$ .

*Abnormality in signal transduction system in CHS platelets—a clue to understanding signal transduction system of collagen receptor:* Although a number of candidates have been proposed as collagen receptors to date, several lines of evidence have indicated that glycoprotein (GP) VI and GPIa/IIa (also termed integrin  $\alpha 2\beta 1$ ) are predominant receptors for collagen in platelets, since a defect in expression of GPIa/IIa or GPVI in human platelets brought about insufficient platelet aggregation response to collagen, while responses to other agonists were normal [38, 43, 65, 71]. GPVI, which belongs to an immunoglobulin superfamily [15], is accepted as a major collagen receptor that mediates platelet activation due to collagen, whereas GPIa/IIa has been suggested to be responsible for the platelet adhesion to collagen [71]. Recently, several tools have been introduced as specific activators of GPVI or GPIa/IIa (Fig. 3). Convulxin, isolated from the snake *Crotalus durissus terrificus* venom, and collagen-related peptide (CRP), which consists of a glycine-proline-hydroxyproline repeat and is cross-linked via cysteine residues at its C- and N-terminals, have been shown to activate platelets by interacting with GPVI [25, 39, 51]. On the other hand, rhodocytin, isolated from the other snake *Calloselasma rhodostoma* venom, was first reported to activate GPIa/IIa [21, 58, 67]. In our study, the GPVI-specific activator convulxin- or CRP-induced increase in  $[\text{Ca}^{2+}]_i$  was normal or only slightly inhibited in bovine CHS platelets [61] (Fig. 2B). On the other hand, an increase in  $[\text{Ca}^{2+}]_i$  induced by rhodocytin was greatly depressed in CHS platelets when the influence of endogenous agonists was excluded (Fig. 2C). GPIa/IIa-dependent adhesion of CHS platelets to type I collagen was not different from that of normal platelets, suggesting that the GPIa/IIa receptor is expressed normally on CHS platelets and collagen can bind to it in a way similar to normal platelets [61]. These data led us to deduce a tentative idea that GPIa/IIa-dependent signaling system is impaired in CHS platelets. However, Bergmeier *et al.* [7] recently reported that rhodocytin induced platelet activation in platelets from  $\beta 1$  integrin (GPIIa)-null mice. Moreover, mouse platelets lacking both  $\alpha 2\beta 1$  integrin (GPIa/IIa) and GPVI responded normally to rhodocytin, suggesting that rhodocytin does not bind to GPIa/IIa at least in mice. This is contradictory to the

Suzuki-Inoue group's finding that rhodocytin bound to recombinant human GPIa/IIa [67]. Hence, the site of action of rhodocytin has been thrown into argument. As for bovine platelets, there are some common features between the collagen- and rhodocytin-induced responses; the response to collagen or rhodocytin was similarly sensitive to cytochalasin D, an actin polymerization inhibitor, but that to convulxin was insensitive to cytochalasin D, and CHS platelets showed a similar decrease of sensitivity to collagen and rhodocytin [61]. From these, it is very conceivable that the rhodocytin-sensitive mechanism is involved in the collagen-induced activation of platelets and a defect in the rhodocytin-sensitive mechanism is related to dysfunction of CHS platelets.

The understanding that GPIa/IIa functions as a receptor for the adhesion of platelets to collagen and GPVI for the platelet activation has to be reassessed [71]. Recently the study by Nieswandt *et al.* [42] using  $\beta 1$  knock out mice showed that GPIa/IIa is not essential for the collagen-induced aggregation. Thus, it should be determined whether GPIa/IIa is truly involved in the collagen-induced activation in bovine platelets. If not, what receptor other than GPVI is important for the activation? Figure 3 shows a speculative model for platelet collagen receptors. It has been reported that GPIa/IIa and GPVI are not independent of each other, but are likely to exchange signals, because upon stimulation of platelets by CRP, GPIa/IIa can be converted to a form with high affinity for soluble collagen [22], and a topographic association between GPIa/IIa and GPVI has been suggested [23]. From the following data, we think that GPVI may not be activated by collagen without help from another receptor system. When the influence of endogenous agonists was excluded, collagen scarcely increased  $[\text{Ca}^{2+}]_i$  in CHS platelets [61]. Since the GPVI-mediated signaling (response to convulxin or CRP) was normal in CHS platelets and the binding of collagen to GPIa/IIa was normal [61], collagen should have been able to increase  $[\text{Ca}^{2+}]_i$  via a GPVI-mediated pathway in these platelets. Nevertheless, the response to collagen was very weak in CHS platelets. This means that a signal from other receptor system is required for full activation of GPVI when collagen acts on platelets. Probably cooperation between collagen receptors, such as GPVI and GPIa/IIa, or in other words GPVI and the rhodocytin-sensitive mechanism, determines the adhesion and the platelet activation in the collagen-induced response. It is possible that a signal from the rhodocytin-sensitive mechanism plays an auxiliary role for the GPVI-dependent pathway. The extremely depressed  $\text{Ca}^{2+}$  signaling as a result of direct action of collagen in CHS platelets suggests that collagen-induced  $\text{Ca}^{2+}$  mobilization requires both signals from GPVI and other collagen receptor(s).

## PERSPECTIVES

Recently, the gene responsible for CHS has been cloned in humans, mice and Japanese Black cattle [3, 28, 40]. The gene associated with CHS in these species encodes a novel

400-kDa protein, LYST, which stands for lysosome trafficking regulator. So far, biological functions of the LYST protein are not completely understood. At least it is possible that a defect in this gene is related to an abnormality of dense body function ( $\delta$ -SPD) [20]. It is an important issue to clarify how alteration in LYST gene produces a defect in a protein responsible for the collagen receptor -  $\text{Ca}^{2+}$  signaling system in CHS platelets.

The available data at this moment demonstrate that CHS platelets have a defect in a signal transduction system associated with a type of collagen receptor other than GPVI. Now, the scheme that GPIa/IIa plays a role for adhesion and GPVI for platelet activation has become more complicated than ever and has to be reconstructed. Considering that the mechanism for platelet aggregation to collagen is very different among animal species [24], the role of each collagen receptor could be different depending on species. To reassess the mechanism of collagen-dependent signal transduction system, rhodocytin is a good tool and CHS platelets are a good model. Identification of target of rhodocytin is important at this moment. The rhodocytin binding protein could be GPIa/IIa itself, another receptor that interacts with GPIa/IIa or a molecule that is independent of GPIa/IIa and transmits a signal to GPVI (Fig. 3). Further study to explore the etiology of insufficient aggregation of CHS platelets will provide the information about the crosstalk among collagen receptors and the mechanism of hemostasis.

**ACKNOWLEDGMENTS.** This study was supported by a Grant-in-Aid from Scientific Research from Japan Society for the Promotion of Science and grants from the Morinaga Hoshi-kai and the Ito Foundation. We appreciate Dr. Masaaki Moroi at Department of Protein Biochemistry, Institute of Life Science, Kurume University, Drs. Takashi Morita and Yangchol Shin at Department of Biochemistry, Meiji College of Pharmacy for helpful advice, Takeshi Fujishiro and Kiichi Fukuyama at Miyazaki University Farm Sumiyoshi Ranch for technical assistance.

#### REFERENCES

1. Apitz-Castro, R., Cruz, M. R., Ledezma, E., Merino, F., Ramirez-Duque, P., Dangelmeier, C. and Holmsen, H. 1985. The storage pool deficiency in platelets from humans with the Chédiak-Higashi syndrome: study of six patients. *Br. J. Haematol.* **59**: 471–483.
2. Ayers, J. R., Leipold, H. W. and Padgett, G. A. 1988. Lesions in Brangus cattle with Chédiak-Higashi syndrome. *Vet. Pathol.* **25**: 432–436.
3. Barbosa, M. D. F. S., Nguyen, Q. A., Tchernev, V. T., Ashley, J. A., Detter, J. C., Blaydes, S. M., Brandt, S. J., Chotai, D., Hodgman, C., Solari, R. C. E., Lovett, M. and Kingsmore, S. F. 1996. Identification of the homologous beige and Chédiak-Higashi syndrome genes. *Nature (Lond.)* **382**: 262–265.
4. Baguez-Cesar, A. B. 1943. Neutoropenia cronica maligna familiar con granulaciones atipicas de los leucocitos. *Bol. Soc. Cubana Pediatr.* **15**: 900–922.
5. Bell, T. G., Meyers, K. M., Prieur, D. J., Fauci, A. S., Wolff, S. M. and Padgett, G. A. 1976. Decreased nucleotide and serotonin storage associated with defective function in Chédiak-Higashi syndrome cattle and human platelets. *Blood* **48**: 175–184.
6. Bell, T. G., Padgett, G. A., Patterson, W. R., Meyers, K. M. and Gorham, J. R. 1980. Prolonged bleeding time in Aleutian mink associated with a cyclo-oxygenase-independent aggregation defect and nucleotide deficit in blood platelets. *Am. J. Vet. Res.* **41**: 910–914.
7. Bergmeier, W., Bouvard, D., Eble, J. A., Mokhtari-Nejad, R., Schulte, V., Zirngibl, H., Brakebusch, C., Fassler, R. and Nieswandt, B. 2001. Rhodocytin (aggrexin) activates platelets lacking  $\alpha\beta 1$  integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Iba. *J. Biol. Chem.* **276**: 25121–25126.
8. Berridge, M. J. 1993. Inositol trisphosphate and calcium signalling. *Nature (Lond.)* **361**: 315–325.
9. Berridge, M. J. and Irvine, R. F. 1984. Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature (Lond.)* **312**: 315–321.
10. Bleasdale, J. E., Thakur, N. R., Gremban, R. S., Bundy, G. L., Fitzpatrick, F. A., Smith, R. J. and Bunting, S. 1990. Selective inhibition of receptor coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. *J. Pharmacol. Exp. Ther.* **255**: 756–768.
11. Bondy, G. S. and Gentry, P. A. 1989. Characterization of the normal bovine platelet aggregation response. *Comp. Biochem. Physiol.* **92c**: 67–72.
12. Buchanan, G. R. and Handin, R. I. 1976. Platelet function in the Chédiak-Higashi Syndrome. *Blood* **47**: 941–948.
13. Boxer, G. J., Holmsen, H., Robkin, L., Bang, N. U., Boxer, L. A. and Baehner, R. L. 1977. Abnormal platelet function in Chédiak-Higashi syndrome. *Br. J. Haematol.* **35**: 521–533.
14. Chédiak, M. 1952. Nouvelle anomalie leucocytaire de caractère constitutionnel et familial. *Rev. Hematol.* **7**: 362–367.
15. Clemetson, J. M., Polgar, J., Magnenat, E., Wells, T. N. and Clemetson, K. J. 1999. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to Fc $\alpha$ R and the natural killer receptors. *J. Biol. Chem.* **274**: 29019–29024.
16. Cowles, B. E., Meyers, K. M., Wardrop, K. J., Menard, M. and Sylvester, D. 1992. Prolonged bleeding time of Chédiak-Higashi cats corrected by platelet transfusion. *Thromb. Haemost.* **67**: 708–712.
17. Gentry, P. A., Tremblay, R. R. M. and Ross, M. L. 1989. Failure of aspirin to impair bovine platelet function. *Am. J. Vet. Res.* **50**: 919–922.
18. Gordon, J. L. 1986. Extracellular ATP: effects, sources and fate. *Biochem. J.* **233**: 309–319.
19. Higashi, O. 1954. Congenital gigantism of peroxidase granules. *Tohoku J. Exp. Med.* **59**: 315–332.
20. Huizing, M., Anikster, Y. and Gahl, W. A. 2001. Hermansky-Pudlak syndrome and Chédiak-Higashi syndrome: disorders of vesicle formation and trafficking. *Thromb. Haemost.* **86**: 233–245.
21. Inoue, K., Ozaki, Y., Satoh, K., Wu, Y., Yatomi, Y., Shin, Y. and Morita, T. 1999. Signal transduction pathways mediated by glycoprotein Ia/IIa in human platelets: comparison with those of glycoprotein VI. *Biochem. Biophys. Res. Commun.* **256**: 114–120.
22. Jung, S. M. and Moroi, M. 1998. Platelets interact with soluble and insoluble collagens through characteristically different reactions. *J. Biol. Chem.* **273**: 14827–14837.
23. Kamiguti, A. S., Theakston, R. D. G., Watson, S. P., Bon, C., Laing, G. D. and Zuzel, M. 2000. Distinct contributions of gly-



- coprotein VI and  $\alpha 2\beta 1$  integrin to the induction of platelet protein tyrosine phosphorylation and aggregation. *Arch. Biochem. Biophys.* **374**: 356–362.
24. Kawashima, S., Shiraiishi, M., Fujishiro, T., Fukuyama, K. and Ito, K. 2001. Different mechanisms responsible for collagen-induced activation of human and bovine platelets. *Jpn. J. Pharmacol.* **85** (Suppl.): 179P.
  25. Kehrel, B., Wierwille, S., Clemetson, K. J., Anders, O., Steiner, M., Knight, C. G., Farndale, R. W., Okuma, M. and Barnes, M. J. 1998. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. *Blood* **91**: 491–499.
  26. Kim, H. K., Kim, J. W., Zilberstein, A., Margolis, B., Kim, J. G., Schlessinger, J. and Rhee, S. G. 1991. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. *Cell* **65**: 435–441.
  27. Kramer, J. W., Davis, W. C. and Prieur, D. J. 1977. The Chediak-Higashi syndrome of cats. *Lab. Invest.* **36**: 554–562.
  28. Kunieda, T., Nakagiri, M., Takami, M., Ide, H. and Ogawa, H. 1999. Cloning of bovine *LYST* gene and identification of a missense mutation associated with Chediak-Higashi syndrome of cattle. *Mamm. Genome.* **10**: 1146–1149.
  29. Leader, R. W., Padgett, G. A. and Gorham, J. R. 1963. Studies of abnormal leukocyte bodies in the mink. *Blood* **22**: 477–484.
  30. Legrand, C. and Nurden, A. T. 1985. Studies on platelets of patients with inherited platelet disorders suggest that collagen-induced fibrinogen binding to membrane receptors requires secreted ADP but not released  $\alpha$ -granule proteins. *Thromb. Haemost.* **54**: 603–606.
  31. Lutzner, M. A., Lowrie, C. T. and Jordan, H. W. 1967. Giant granules in leukocytes of the beige mouse. *J. Hered.* **58**: 299–300.
  32. McNicol, A. and Israels, S. J. 1999. Platelet dense granules: structure, function and implications for haemostasis. *Thromb. Res.* **95**: 1–18.
  33. Meyers, K. M., Holmsen, H., Seachord, C. L., Hopkins, G. E., Borchard, R. E. and Padgett, G. A. 1979. Storage pool deficiency in platelets from Chediak-Higashi cattle. *Am. J. Physiol.* **237**: R239–R248.
  34. Meyers, K. M., Hopkins, G., Holmsen, H., Benson, K. and Prieur, D. J. 1982. Ultrastructure of resting and activated storage pool deficient platelets from animals with the Chediak-Higashi syndrome. *Am. J. Pathol.* **106**: 364–377.
  35. Meyers, K. M., Seachord, C. L., Holmsen, H. and Prieur, D. J. 1981. Evaluation of the platelet storage pool deficiency in the feline counterpart of the Chediak-Higashi syndrome. *Am. J. Hematol.* **11**: 241–253.
  36. Ménard, M. and Meyers, K. M. 1988. Storage pool deficiency in cattle with the Chédiak-Higashi syndrome results from an absence of dense granule precursors in their megakaryocytes. *Blood* **72**: 1726–1734.
  37. Menard, M., Meyers, K. M. and Prieur, D. J. 1990. Primary and secondary lysosomes in megakaryocytes and platelets from cattle with the Chediak-Higashi syndrome. *Thromb. Haemost.* **64**: 156–160.
  38. Moroi, M., Jung, S. M., Okuma, M. and Shinmyozu, K. 1989. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. *J. Clin. Invest.* **84**: 1440–1445.
  39. Morton, L. F., Hargreaves, P. G., Farndale, R. W., Young, R. D. and Barnes, M. J. 1995. Integrin  $\alpha 2\beta 1$ -independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for  $\alpha 2\beta 1$ -independent platelet reactivity. *Biochem. J.* **306**: 337–344.
  40. Nagle, D. L., Karim, M. A., Woolf, E. A., Holmgren, L., Bork, P., Misumi, D. J., McGrail, S. H., Dussault, B. J., Perou, C. M., Boissy, R. E., Duyk, G. M., Spritz, R. A. and Moore, K. J. 1996. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. *Nature Genet.* **14**: 307–311.
  41. Nakano, T., Hanasaki, K. and Arita, H. 1989. Possible involvement of cytoskeleton in collagen-stimulated activation of phospholipase in human platelets. *J. Biol. Chem.* **264**: 5400–5406.
  42. Nieswandt, B., Brakebusch, C., Bergmeier, W., Schulte, V., Bouvard, D., Mokkhtari-Nejad, R., Lindhout, T., Heemskerk, J. W. M., Zimigibl, H. and Fässler, R. 2001. Glycoprotein VI but not  $\alpha 2\beta 1$  integrin is essential for platelet interaction with collagen. *EMBO J.* **20**: 2120–2130.
  43. Nieuwenhuis, H. K., Akkerman, J. W. N., Houdijk, W. P. M. and Sixma, J. J. 1985. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. *Nature (Lond.)* **318**: 470–472.
  44. Nieuwenhuis, H. K., Akkerman, J. W. N. and Sixma, J. J. 1987. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. *Blood* **70**: 620–623.
  45. Nishimura, M., Inoue, M., Nakano, T., Nishikawa, T., Miyamoto, M., Kobayashi, T. and Kitamura, Y. 1989. Beige rat: a new animal model of Chediak-Higashi syndrome. *Blood* **74**: 270–273.
  46. Ogawa, H., Tu, C-H., Kagamizono, H., Soki, K., Inoue, Y., Akatsuka, H., Nagata, S., Wada, T., Ikeya, M., Makimura, S., Uchida, K., Yamaguchi, R. and Otsuka, H. 1997. Clinical, morphologic, and biochemical characteristics of Chediak-Higashi syndrome in fifty-six Japanese Black cattle. *Am. J. Vet. Res.* **58**: 1221–1226.
  47. Ozaki, K., Fujimori, H., Nomura, S., Nishikawa, T., Nishimura, M., Pan-Hou, H. and Narama, I. 1998. Morphologic and hematologic characteristics of storage pool deficiency in beige rats (Chediak-Higashi syndrome of rats). *Lab. Anim. Sci.* **48**: 502–506.
  48. Padgett, G. A., Leader, R. W., Gorham, J. R. and O'Mary, C. C. 1964. The familial occurrence of the Chediak-Higashi syndrome in mink and cattle. *Genetics* **49**: 505–512.
  49. Padgett, G. A., Reiquam, C. W., Gorham, J. R., Henson, J. B. and O'Mary, C. C. 1967. Comparative studies of the Chediak-Higashi syndrome. *Am. J. Pathol.* **51**: 553–571.
  50. Parmley, R. T., Poon, M. C., Crist, W. M. and Malluh, A. 1979. Giant platelet granules in a child with the Chediak-Higashi syndrome. *Am. J. Hematol.* **6**: 51–60.
  51. Polgar, J., Clemetson, J. M., Kehrel, B. E., Wiedemann, M., Magnenat, E. M., Wells, T. N. C. and Clemetson, K. J. 1997. Platelet activation and signal transduction by Convulxin, a C-type lectin from *Crotalus durissus terrificus* (tropical rattlesnake) venom via the p62/GPVI collagen receptor. *J. Biol. Chem.* **272**: 13576–13583.
  52. Pollock, W. K., Rink, T. J. and Irvine, R. F. 1986. Liberation of [<sup>3</sup>H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. *Biochem. J.* **235**: 869–877.
  53. Pratt, H. L., Carroll, R. C., Jones, J. B. and Lothrop, C. D. 1991. Platelet aggregation, storage pool deficiency, and protein phosphorylation in mice with Chediak-Higashi syndrome. *Am.*

- J. Vet. Res.* **52**: 945–950.
54. Prieur, D. J., Holland, J. M., Bell, T. G. and Young, D. M. 1976. Ultrastructural and morphometric studies of platelets from cattle with the Chediak-Higashi syndrome. *Lab. Invest.* **35**: 197–204.
  55. Rendu, F., Breton-Gorius, J., Lebreton, M., Klebanoff, C., Buriot, D., GrisCELLI, C., Levy-Toledano, S. and Caen, J. P. 1983. Evidence that abnormal platelet functions in human Chediak-Higashi syndrome are the result of a lack of dense bodies. *Am. J. Pathol.* **111**: 307–314.
  56. Ruggeri, Z. M. 1997. Mechanisms initiating platelet thrombus formation. *Thromb. Haemost.* **78**: 611–616.
  57. Rink, T. J. and Sage, S. O. 1990. Calcium signaling in human platelets. *Annu. Rev. Physiol.* **52**: 431–449.
  58. Shin, Y. and Morita, T. 1998. Rhodocytin, a functional novel platelet agonist belonging to the heterodimer C-type lectin family, induces platelet aggregation independently of glycoprotein Ib. *Biochem. Biophys. Res. Commun.* **245**: 741–745.
  59. Shiraishi, M., Ikeda, M., Ogawa, H., Tu, C-H. and Ito, K. 1998. Impaired cytosolic calcium mobilization and aggregation in response to collagen in platelets from Japanese Black cattle with Chediak-Higashi syndrome. *Am. J. Vet. Res.* **59**: 744–749.
  60. Shiraishi, M., Ikeda, M., Fujishiro, T., Fukuyama, K. and Ito, K. 2000. Characteristics of collagen-induced  $Ca^{2+}$  mobilization in bovine platelets. *Cell Calcium.* **27**: 53–60.
  61. Shiraishi, M., Kawashima, S., Moroi, M., Shin, Y., Morita, T., Horii, Y., Ikeda, M. and Ito, K. 2002. A defect in collagen receptor- $Ca^{2+}$  signaling in platelets from cattle with Chediak-Higashi syndrome. *Thromb. Haemost.* **87**: 334–341.
  62. Siess, W., Cuatrecasas, P. and Lapetina, E. G. 1983. A role for cyclooxygenase products in the formation of phosphatidic acid in stimulated human platelets. *J. Biol. Chem.* **258**: 4683–4686.
  63. Sjaastad, O. V., Blom, A. K., Stormorken, H. and Nes, N. 1990. Adenine nucleotides, serotonin, and aggregation properties of platelets of blue foxes (*Alopex lagopus*) with the Chediak-Higashi syndrome. *Am. J. Med. Genet.* **35**: 373–378.
  64. Smith, J. B., Selak, M. A., Dangelmaier, C. and Daniel, J. L. 1992. Cytosolic calcium as a second messenger for collagen-induced platelet responses. *Biochem. J.* **288**: 925–929.
  65. Sugiyama, T., Okuma, M., Ushikubi, F., Sensaki, S., Kanaji, K. and Uchino, H. 1987. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. *Blood* **69**: 1712–1720.
  66. Suzuki, T., Goryo, M., Inanami, O., Uetsuki, J., Saito, S., Kaketa, K., Oshima, T., Shimizu, H., Okabe, S., Tanaka, T., Kamata, R., Shuto, F., Sato, I., Tachikawa, E., Sakaguchi, M., Kobayashi, H. and Okada, K. 1996. Inhibition of collagen-induced platelet aggregation in Japanese Black cattle with inherited platelet disorder, Chediak-Higashi syndrome. *J. Vet. Med. Sci.* **58**: 647–654.
  67. Suzuki-Inoue, K., Ozaki, Y., Kainoh, M., Shin, Y., Wu, Y., Yatomi, Y., Ohmori, T., Tanaka, T., Satoh, K. and Morita, T. 2001. Rhodocytin induces platelet aggregation, by interacting with glycoprotein Ia/IIa (GPIa/IIa, integrin  $\alpha 2\beta 1$ ): involvement of GPIa/IIa-associated Src and protein tyrosine phosphorylation. *J. Biol. Chem.* **276**: 1643–1652.
  68. Tu, C-H., Takahashi, Y., Kaseda, Y., Uchida, K., Yamaguchi, R., Suzuki, K., Ogawa, H. and Otsuka, H. 1996. Inheritance of Chediak-Higashi syndrome in Japanese black cattle. *J. Vet. Med. Sci.* **58**: 501–504.
  69. Umemura, T., Katsuta, O., Goryo, M., Hayashi, T. and Itakura, C. 1983. Pathological findings in a young Japanese Black cattle affected with Chediak-Higashi syndrome. *Jpn. J. Vet. Sci.* **45**: 241–246.
  70. Vickers, J. D. 1993. U73122 affects the equilibria between the phosphoinositides as well as phospholipase C activity in unstimulated and thrombin-stimulated human and rabbit platelets. *J. Pharmacol. Exp. Ther.* **266**: 1156–1163.
  71. Watson, S. P. 1999. Collagen receptor signaling in platelets and megakaryocytes. *Thromb. Haemost.* **82**: 365–376.
  72. Watson, S. P. and Gibbins, J. 1998. Collagen receptor signaling in platelets: extending the role of the ITAM. *Immunol. Today* **19**: 260–264.
  73. Weening, R. S., Schoorel, E. P., Roos, D., van Schaik, M. L. J., Voetman, A. A., Bot, A. A. M., Batenburg-Plenter, A. M., Willems, C., Zeijlemaker, W. P. and Astaldi, A. 1981. Effect of ascorbate on abnormal neutrophil, platelet, and lymphocyte function in a patient with the Chediak-Higashi syndrome. *Blood* **57**: 856–865.

**The Journal of Veterinary Medical Science 和 文 要 約**  
第 64 卷, 第 9 号, 平成 14 年 9 月

**総 説:**

- チェディアック・東症候群の牛における血小板機能異常——白石光也<sup>1)</sup>・小川博之<sup>2)</sup>・池田正浩<sup>1)</sup>・川島幸子<sup>1)</sup>・伊藤勝昭<sup>1)</sup>(<sup>1)</sup>宮崎大学農学部家畜薬理学講座, <sup>2)</sup>東京大学農学生命研究科高度医療科学講座)..... 751-760**

人, 牛, マウス, ミンク等で認められるチェディアック・東症候群(CHS)の牛における重大な症状は出血傾向であり, それはコラーゲンに対する反応低下による血小板凝集不全に起因する。凝集不全の原因としてコラーゲン刺激によって生じるADPやトロンボキサンA2などの内因性アゴニストの関与が低下していることが考えられている。しかし, 内因性アゴニスト阻害薬を用いた実験から, 牛血小板のコラーゲン凝集においてこれら2次性アゴニストの役割は小さく, 反応低下の主要な原因はむしろコラーゲンによるホスホリパーゼC活性化の抑制であり, そのためCa<sup>2+</sup>動員が抑制されていると考えられる。コラーゲンレセプターは数種類存在し, これらが共同して凝集を起こすが, そのシグナル伝達機構については不明な点が多い。当初, コラーゲンレセプターのひとつであるGPIIb/IIIa(インテグリン $\alpha 2\beta 1$ )のアゴニストであると報告された rhodocytin は, CHS 血小板ではきわめて抑制された反応を起こした。rhodocytin の作用部位ははまだ確定していないが, rhodocytin に感受性のある機構が欠損していることがCHS血小板の機能異常に関与していることが示唆される。CHS血小板は複雑なコラーゲンレセプターの相互関係を解明するのに有用である。

**解 剖 学:**

- ニホンジカ象牙質における日周期成長線——飯沼康子<sup>1)</sup>・鈴木正嗣<sup>1)</sup>・横山真弓<sup>2)</sup>・田中中村友香<sup>1)</sup>・大泰司紀之<sup>1)</sup>(<sup>1)</sup>北海道大学大学院獣医学研究科生態学教室, <sup>2)</sup>兵庫県立人と自然の博物館自然・環境マネジメント研究部)..... 791-795**

ニホンジカ当歳獣の象牙質内成長線について観察を行い, 蛍光色素投与による時刻描記法を用いて周期性を検討した。微細成長線は脱灰薄切片のBodian染色標本で観察し, 一方, 蛍光ラベリング線は非脱灰研磨標本で観察した。Bodianの鍍銀染色標本では2種の線条が認められた。ひとつは細く淡染された規則的な微細成長線で, もうひとつはより太く濃染された線条である。濃染された好銀線の間隔や染色濃度のパターンは同一試料から得られた研磨標本の蛍光ラベリング線のものと同じであった。そのため蛍光色素沈着線はBodian染色により好銀線として染め出されるものと考えられた。濃染されたラベリング線間の成長線本数は各蛍光色素の投与間隔日数と一致しており, この微細成長線が日周期を持つものであることが示唆された。この日周期成長線を用いた日齢査定の可能性について議論を行い, また本研究で用いた蛍光色素(オキシテトラサイクリン, カルセイン)の有用性についても併せて検討した。

- 馬網膜の内顆粒層を構成する各種細胞の定量的研究(短報)——郭 暁麗<sup>1,2)</sup>・杉田昭栄<sup>1)</sup>(<sup>1)</sup>宇都宮大学農学部動物機能形態学研究室, <sup>2)</sup>東京農工大学大学院連合農学研究科)..... 847-849**

馬の網膜内顆粒層にある双極細胞, アマクリン細胞, 水平細胞およびミュラー細胞を数量的に検索した。各種細胞は突起および細胞学的特徴を基準に同定した。馬の網膜内顆粒層における4種類の細胞の平均割合はそれぞれ44%, 24%, 1%, 29%であった。また, 網膜帯状中心野, 頭頂側部, 鼻側部, 腹側部および背側部における内顆粒層総細胞の密度もそれぞれ算出した。

- 山羊の近軸性橈骨半肢3例のX線学的所見(短報)——Corbera, J. A.<sup>1)</sup>・Pulido, M.<sup>1)</sup>・Moralis, M.<sup>1)</sup>・Juste, M. C.<sup>1)</sup>・Gutierrez, C.<sup>1)</sup>(<sup>1)</sup>Department of Animal Medicine and Surgery, Veterinary Faculty, University of Las Palmas de Gran Canaria, Spain).... 843-845**